Shareholders of Amedisys (NASDAQ: AMED) have voted in favor of the company’s pending acquisition by the UnitedHealth Group (NYSE: UNH) subsidiary Optum.
Optum in June penned a deal to acquire Amedisys in an all-cash transaction of $101 per share, or about $3.3 billion. The transaction followed a previous offer to acquire Amedisys by the home infusion company Option Care Health (NASDAQ: OPCH) for $3.6 billion.
Amedisys’ board recommended that stockholders vote to approve the acquisition, according to an August filing with the SEC, Hospice News reports. Read more.
